CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approval based on a positive subgroup signal.
comments(0)
5-min edit window · permanent after that